☰

Shannon L. Werner, Ph.D. - Publications

Affiliations: 
Chemistry University of California, San Diego, La Jolla, CA 
Area:
signaling, transcription, computational network; stress and immune responses, apoptosis, proliferation
Tree Info Similar researchers PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, Fitzgerald JB, Nielsen UB, Wolf BB. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic. Molecular Cancer Therapeutics. 14: 1625-36. PMID 25911688 DOI: 10.1158/1535-7163.Mct-14-0772  0.688
2013 Behar M, Barken D, Werner SL, Hoffmann A. The dynamics of signaling as a pharmacological target. Cell. 155: 448-61. PMID 24120141 DOI: 10.1016/J.Cell.2013.09.018  0.742
2011 Tan G, Kearns JD, Gerami-Moayed N, Kohli N, Werner SL, King AM, Sloss CM, Bukhalid R, Nielsen UB. Abstract A210: Mechanism of action of MM-151, a potent mixture of three human antibody antagonists targeting EGFR. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A210  0.677
2011 Werner SL, Tan G, Kearns JD, King AM, Sloss C, Gerami-Moayed N, Bukhalid R, Nielsen UB. Abstract A144: Therapeutically targeting high-affinity ligand activation of EGFR with MM-151, an oligoclonal therapeutic. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A144  0.671
2008 Werner SL, Kearns JD, Zadorozhnaya V, Lynch C, O'Dea E, Boldin MP, Ma A, Baltimore D, Hoffmann A. Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20. Genes & Development. 22: 2093-101. PMID 18676814 DOI: 10.1101/Gad.1680708  0.75
2007 O'Dea EL, Barken D, Peralta RQ, Tran KT, Werner SL, Kearns JD, Levchenko A, Hoffmann A. A homeostatic model of IkappaB metabolism to control constitutive NF-kappaB activity. Molecular Systems Biology. 3: 111. PMID 17486138 DOI: 10.1038/Msb4100148  0.724
2007 Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, Hoffmann A. A fourth IkappaB protein within the NF-kappaB signaling module. Cell. 128: 369-81. PMID 17254973 DOI: 10.1016/J.Cell.2006.12.033  0.777
2006 Kearns JD, Basak S, Werner SL, Huang CS, Hoffmann A. IkappaBepsilon provides negative feedback to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression. The Journal of Cell Biology. 173: 659-64. PMID 16735576 DOI: 10.1083/Jcb.200510155  0.774
2006 Cheong R, Bergmann A, Werner SL, Regal J, Hoffmann A, Levchenko A. Transient IkappaB kinase activity mediates temporal NF-kappaB dynamics in response to a wide range of tumor necrosis factor-alpha doses. The Journal of Biological Chemistry. 281: 2945-50. PMID 16321974 DOI: 10.1074/Jbc.M510085200  0.674
2006 Kearns JD, Basak S, Werner SL, Huang CS, Hoffmann A. IκBε provides negative feedback to control NF-κB oscillations, signaling dynamics, and inflammatory gene expression Journal of Experimental Medicine. 203: i18-i18. DOI: 10.1084/JEM2036OIA18  0.728
2005 Werner SL, Barken D, Hoffmann A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science (New York, N.Y.). 309: 1857-61. PMID 16166517 DOI: 10.1126/Science.1113319  0.773
Show low-probability matches.